-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 R0j/CT6ebkEK1VNZ7ZyhA1HG3Js31ySofZgCXNxlHmHPNZNjBTozW3HO6SrvKhgf
 VG/2nTgKQ8jvbpEFjirXWA==

<SEC-DOCUMENT>0001167379-02-000056.txt : 20021001
<SEC-HEADER>0001167379-02-000056.hdr.sgml : 20021001
<ACCEPTANCE-DATETIME>20021001120039
ACCESSION NUMBER:		0001167379-02-000056
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20020930
FILED AS OF DATE:		20021001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALCON INC
		CENTRAL INDEX KEY:			0001167379
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980205094
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31269
		FILM NUMBER:		02777862

	BUSINESS ADDRESS:	
		STREET 1:		6201 SOUTH FREEWAY
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76134
		BUSINESS PHONE:		8175516878

	MAIL ADDRESS:	
		STREET 1:		BOSCH 69 6331 HUNENBERG
		CITY:			SWITZERLAND
		STATE:			V8
		ZIP:			0000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>acl6knewsrelease092802.htm
<DESCRIPTION>OFFICIAL HTML FILING
<TEXT>
<HTML>
<HEAD>
<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>A</TITLE>
</HEAD>
<BODY LINK="#0000ff">

<B><FONT SIZE=5><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</P>
</B></FONT><P ALIGN="CENTER">Washington, D.C. 20549</P>
<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=4><P ALIGN="CENTER">FORM 6-K</P>
</B></FONT><FONT SIZE=3><P ALIGN="CENTER"></P>
</FONT><B><P ALIGN="CENTER">Report Of Foreign Issuer</P>
<P ALIGN="CENTER">Pursuant To Rule 13a-16 Or 15d-16 of</P>
<P ALIGN="CENTER">the Securities Exchange Act of 1934</P>
</B><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><P ALIGN="CENTER">For the month of September 2002</P>
<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=5><P ALIGN="CENTER">ALCON, INC.</P>
</B></FONT><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">B</FONT><FONT FACE="Tahoma" SIZE=3>&ouml;</FONT><FONT SIZE=3>sch 69</P>
<P ALIGN="CENTER">P.O. Box 62</P>
<P ALIGN="CENTER">6331 H&uuml;nenberg, Switzerland</P>
<P ALIGN="CENTER">011-41-41-785-8888</P>
<P ALIGN="CENTER">(Address of principal executive offices)</P>
<P ALIGN="CENTER"></P>
<P>[Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.]</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=696>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Form 20-F <U>   x</U></FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Form 40-F</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER"></P>
<P>&#9;&#9;&#9;</P>
<P ALIGN="CENTER"></P>
<P>[Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.]</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=696>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Yes</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">No   <U>    x</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</FONT><FONT SIZE=2><P>&nbsp;</P>
</FONT><FONT SIZE=3><P>Incorporation by Reference</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">This Report of Foreign Issuer on Form 6-K shall be incorporated by reference into the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 24, 2002.</P>
</FONT><FONT SIZE=2>
<P>&nbsp;</P>
</FONT><P>The following press release was issued by Alcon Research, Ltd., a wholly owned subsidiary of Alcon, Inc., on September 28, 2002.</P>
<FONT SIZE=2><P ALIGN="CENTER">&#9;</P>
</FONT><FONT FACE="Arial" COLOR="#000080"><P ALIGN="RIGHT">Alcon Research Ltd.</P>
<P ALIGN="RIGHT">6201 South Freeway</P>
<P ALIGN="RIGHT">Fort Worth, TX 76134</P>
</FONT><B><I><U><FONT FACE="Arial"><P>For immediate release</P>

</I></U><P>Anecortave Acetate Continues to Show </P>
<P>Powerful Efficacy in Clinical Trials for </P>
<P>Age-Related Macular Degeneration </P>
</B>
<B><P>FORT WORTH, Texas -</B> <B>September 28 -</B> Anecortave Acetate, Alcon, Inc.'s investigational new drug, continued to demonstrate effectiveness in reducing vision loss in patients with the wet form of age-related macular degeneration. The 12-month data from an ongoing study demonstrated that Anecortave Acetate 15mg was significantly better at preserving vision, preventing severe vision loss and inhibiting lesion growth in the retina than a placebo. </P>
<P>Of patients treated with Anecortave Acetate15mg, 79 percent lost fewer than three lines of vision from baseline at the month 12 visit, compared to 53 percent of patients in the placebo group (statistically significant, p&lt; 0.05). In the sub-group of patients with predominantly classic lesions, which are more severe, the month 12 clinical efficacy was even more pronounced, with 84 percent of treated patients maintaining vision within three lines compared to 50 percent for the placebo group (statistically significant, p&lt;0.05).</P>
<P>Dr. Jason Slakter, a retinal specialist at Vitreous-Retina-Macula Consultants of New York and Clinical Professor of Ophthalmology at the New York University School of Medicine, presented these findings to Anecortave Acetate clinical investigators preceding the Retina Congress 2002 meeting in San Francisco. &quot;The results in this study are the first reports from any long-term, controlled clinical trial to show safety and efficacy of a pharmacological treatment for wet AMD,&quot; remarked Dr. Slakter. &quot;They represent another step forward for this therapy that could become an important treatment for AMD.&quot; </P>
<P>Alcon has already moved ahead with the next step to gain regulatory approval of Anecortave Acetate by launching a Phase III trial at more than 40 sites in the United States, Europe, Australia and Canada. This study will involve approximately 500 subjects; Alcon investigators are actively enrolling patients. The study directly compares the effectiveness of Anecortave Acetate versus photodynamic therapy (PDT) using Visudyne</FONT><SUP><FONT FACE="Arial" SIZE=1>&reg;</SUP></FONT><FONT FACE="Arial"> in patients diagnosed with predominantly classic wet AMD. PDT with Visudyne is the only approved treatment other than laser photocoagulation for the type of AMD being studied. Because the treatment options for patients are so limited, the potential Anecortave Acetate brings to this field could prove to be a major advance in fighting wet AMD.</P>
<P>Patients interested in participating in this trial, or anyone interested in finding out more about it, may call <B>866-692-5959</B>. Information is also available on Alcon's website, www.alconinc.com, go to USA, then click on clinical studies<B>.</P>
</B><P>Anecortave Acetate is delivered by an injection around and behind the eye (a juxtascleral injection), allowing the medication to be deposited behind the macula, the area where the retina is diseased. Alcon designed a device specifically to administer the injection. Compared to other approved and experimental treatments for AMD, this injection procedure is less invasive and requires less frequent administration (once each six months). It has also been shown to be very safe; more than 500 injections have been performed in Anecortave Acetate clinical trials to date without any clinically relevant safety issues. An independent Safety Committee that provides ongoing review for all Anecortave Acetate studies has also determined that no clinically relevant adverse events related to the drug itself have been found to date. &quot;The safety profile of Anecortave Acetate continues to prove to be excellent,&quot; noted Safety Committee member Dr. Carl Regillo, a retinal specialist at Retinovitreous Associates in
 Wyndmoor, Pennsylvania and director of Retina Clinical Research Unit at Wills Eye Hospital.</P>
<P>AMD is one of the leading causes of blindness, and ophthalmologists are always in search of newer and more effective treatments for this progressive disease that robs people of their sight and independence. AMD is a disease of the macula region in the retina. There are two forms of AMD, &quot;wet&quot; (or exudative), and &quot;dry.&quot; The wet form results from the growth of new blood vessels under the macula. These blood vessels leak and cause the macula to separate from the underlying tissue, resulting in damage and vision loss. </P>
<P>The macula is the part of the retina that allows people to see fine details and is key to central vision. People with the advanced wet form of AMD often see a black or gray &quot;blind spot&quot; when looking straight ahead. They often have to rely on peripheral vision for daily functioning, and routine activities such as driving and reading often are greatly restricted or impossible. Although only about 10 percent of AMD cases are of the wet form, it is more damaging and is almost entirely responsible for severe vision loss due to AMD. Anecortave Acetate works by slowing or stopping the growth of the new blood vessels, which leads to less leakage and less retinal damage. </P>
<P>Alcon, Inc. (NYSE: ACL) is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for over 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders, and other conditions of the eye.</P>

</FONT><FONT FACE="Arial" SIZE=2><P>*Visudyne is a registered trademark of Novartis, AG.</P>
</FONT><FONT FACE="Arial"><P ALIGN="CENTER"># # #</P>
</FONT><B><I><U><FONT FACE="Arial" SIZE=3 COLOR="#000080"><P>Caution Concerning Forward-Looking Statements.</U> </P>
</B><P>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating principally to our ability to complete clinical trials for Anecortave Acetate and file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and the expected benefits of Anecortave Acetate in treating exudative age-related macular degeneration (AMD). These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause futu
re results to differ include, but are not limited to, the following: we may never submit an NDA for Anecortave Acetate to the FDA, or submission and/or approval of the NDA may take longer than we expect; treatments developed by other companies may reach the market sooner or prove to be more effective than Anecortave Acetate; challenges inherent in new product marketing; and government regulation and legislation. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise. </P>

</I></FONT><B><FONT FACE="Arial" COLOR="#000080"><P ALIGN="RIGHT">For information, contact: <BR>
Doug MacHatton (Investor Relations)<BR>
800-400-8599<BR>
News media inquiries: Mary Dulle (Public Relations)<BR>
817-551-8058 </P>
</FONT><FONT FACE="Arial"><P ALIGN="RIGHT">Clinical Trial information call: 866-692-5959</P>
</B></FONT><FONT FACE="Arial" COLOR="#000080"><P ALIGN="RIGHT">For more information see www.alconinc.com.</P>
<P ALIGN="RIGHT">Go to USA, then to Clinical Studies.</P>
</FONT><FONT FACE="Arial">
</FONT><FONT SIZE=2><P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=619>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<B><FONT SIZE=2><P>Alcon, Inc.</B></FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=2><P>(Registrant)</FONT></TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">Date</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=2><P>9/30/02</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">By</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>/s/ Guido Koller</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Name:  Guido Koller</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Title:  Sr. Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">Date</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=2><P>9/30/02</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">By</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>/s/ Stefan Basler</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Name:  Stefan Basler</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P>Title:  Finance Manager</FONT></TD>
</TR>
<TR><TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<FONT SIZE=2>
<P>&nbsp;</P>
<P>&nbsp;</P>
</FONT><FONT FACE="Arial"><P ALIGN="RIGHT">&nbsp;</P></FONT></BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>3
<FILENAME>acl6knewsrelease092802.pdf
<DESCRIPTION>PRINTER FRIENDLY PDF FILING
<TEXT>
<PDF>
begin 644 acl6knewsrelease092802.pdf
M)5!$1BTQ+C(-)>+CS],-"C(R(#`@;V)J#3P\(`TO3&EN96%R:7IE9"`Q(`TO
M3R`R-"`-+T@@6R`W.#0@,C4P(%T@#2],(#(Q,S$S(`TO12`U,3`Y(`TO3B`T
M(`TO5"`R,#<U-2`-/CX@#65N9&]B:@T@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!X<F5F#3(R
M(#$U(`TP,#`P,#`P,#$V(#`P,#`P(&X-"C`P,#`P,#`V-#<@,#`P,#`@;@T*
M,#`P,#`P,3`S-"`P,#`P,"!N#0HP,#`P,#`Q,3@X(#`P,#`P(&X-"C`P,#`P
M,#$S-#<@,#`P,#`@;@T*,#`P,#`P,34S-"`P,#`P,"!N#0HP,#`P,#`Q.3DQ
M(#`P,#`P(&X-"C`P,#`P,#(Q.#4@,#`P,#`@;@T*,#`P,#`P,CDT-R`P,#`P
M,"!N#0HP,#`P,#`S,3(W(#`P,#`P(&X-"C`P,#`P,#0U,C,@,#`P,#`@;@T*
M,#`P,#`P-#<P-"`P,#`P,"!N#0HP,#`P,#`T.#@P(#`P,#`P(&X-"C`P,#`P
M,#`W.#0@,#`P,#`@;@T*,#`P,#`P,3`Q,R`P,#`P,"!N#0IT<F%I;&5R#3P\
M#2]3:7IE(#,W#2]);F9O(#(P(#`@4B`-+U)O;W0@,C,@,"!2(`TO4')E=B`R
M,#<T-2`-+TE$6SPV9&0S93<V,S1B-61D,V,T,&,S-S<R9#(V.3`S-#@P.3X\
M-F1D,V4W-C,T8C5D9#-C-#!C,S<W,F0R-CDP,S0X,#D^70T^/@US=&%R='AR
M968-,`TE)45/1@T@("`@(`TR,R`P(&]B:@T\/"`-+U1Y<&4@+T-A=&%L;V<@
M#2]086=E<R`R,2`P(%(@#2]/=71L:6YE<R`Q."`P(%(@#2]/<&5N06-T:6]N
M(%L@,C0@,"!2("]865H@;G5L;"!N=6QL(&YU;&P@72`-+U!A9V5-;V1E("]5
M<V5.;VYE(`T^/B`-96YD;V)J#3,U(#`@;V)J#3P\("]3(#DU("]/(#$T.2`O
M1FEL=&5R("]&;&%T941E8V]D92`O3&5N9W1H(#,V(#`@4B`^/B`-<W1R96%M
M#0I(B6)@8&`&(@$&%@8&MF0&7@8$X`6*L0(Q1P.#>[>]4A$#0U<76"*R)?SH
MAJ1IZ0?[)BVZK/M4D&T!`P.3!DB&@X'9Q(.!44C%`ZH#"+@8&)P/`6EN(!8&
MB_@Q<',VNIA-W_!B-;.I&L_##@9%I0F)/A*I?(T;S*&6"P&5N0-I)B">"Q!@
M`"U7&]@-96YD<W1R96%M#65N9&]B:@TS-B`P(&]B:@TQ,S@@#65N9&]B:@TR
M-"`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@,C$@,"!2(`TO4F5S
M;W5R8V5S(#(U(#`@4B`-+T-O;G1E;G1S(#,Q(#`@4B`-+TUE9&EA0F]X(%L@
M,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T
M871E(#`@#3X^(`UE;F1O8FH-,C4@,"!O8FH-/#P@#2]0<F]C4V5T(%L@+U!$
M1B`O5&5X="!=(`TO1F]N="`\/"`O5%0R(#(W(#`@4B`O5%0T(#(Y(#`@4B`O
M5%0V(#,S(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,Q(#,T(#`@4B`^/B`-
M+T-O;&]R4W!A8V4@/#P@+T-S-2`S,"`P(%(@/CX@#3X^(`UE;F1O8FH-,C8@
M,"!O8FH-/#P@#2]4>7!E("]&;VYT1&5S8W)I<'1O<B`-+T%S8V5N="`X.3$@
M#2]#87!(96EG:'0@,"`-+T1E<V-E;G0@+3(Q-B`-+T9L86=S(#,T(`TO1F]N
M=$)";W@@6R`M,38W("TS,#<@,3`P.2`Q,#`W(%T@#2]&;VYT3F%M92`O5&EM
M97-.97=2;VUA;B`-+TET86QI8T%N9VQE(#`@#2]3=&5M5B`P(`T^/B`-96YD
M;V)J#3(W(#`@;V)J#3P\(`TO5'EP92`O1F]N="`-+U-U8G1Y<&4@+U1R=654
M>7!E(`TO1FER<W1#:&%R(#,R(`TO3&%S=$-H87(@,3(P(`TO5VED=&AS(%L@
M,C4P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`R-3`@,S,S(#(U,"`P(#`@-3`P
M(#`@-3`P(#4P,"`U,#`@-3`P(#`@#3`@-3`P(#`@,"`P(#`@,"`P(#`@-S(R
M(#`@-S(R(#<R,B`V-C<@-C$Q(#<W."`W-S@@,S@Y(#`@-S<X(#8V-R`-.30T
M(#<R,B`W-S@@-C$Q(#`@-S(R(#4U-B`V-C<@-S(R(#`@,"`W,C(@,"`P(#`@
M,"`P(#`@,"`P(#4P,"`P(`TT-#0@-34V(#0T-"`S,S,@-3`P(#4U-B`R-S@@
M,"`P(#(W."`P(#4U-B`U,#`@-34V(#`@-#0T(#,X.2`S,S,@#34U-B`P(#`@
M-3`P(%T@#2]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG(`TO0F%S949O;G0@
M+U1I;65S3F5W4F]M86XL0F]L9"`-+T9O;G1$97-C<FEP=&]R(#(X(#`@4B`-
M/CX@#65N9&]B:@TR."`P(&]B:@T\/"`-+U1Y<&4@+T9O;G1$97-C<FEP=&]R
M(`TO07-C96YT(#@Y,2`-+T-A<$AE:6=H="`P(`TO1&5S8V5N="`M,C$V(`TO
M1FQA9W,@,S0@#2]&;VYT0D)O>"!;("TQ.#0@+3,P-R`Q,#@Y(#$P,C8@72`-
M+T9O;G1.86UE("]4:6UE<TYE=U)O;6%N+$)O;&0@#2])=&%L:6-!;F=L92`P
M(`TO4W1E;58@,3,S(`T^/B`-96YD;V)J#3(Y(#`@;V)J#3P\(`TO5'EP92`O
M1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E(`TO1FER<W1#:&%R(#,R(`TO3&%S
M=$-H87(@,C4R(`TO5VED=&AS(%L@,C4P(#`@,"`P(#`@,"`P(#`@,S,S(#,S
M,R`P(#`@,C4P(#,S,R`R-3`@,C<X(#4P,"`U,#`@-3`P(#4P,"`U,#`@#34P
M,"`U,#`@-3`P(#4P,"`U,#`@,C<X(#`@,"`P(#`@,"`P(#<R,B`V-C<@-C8W
M(#<R,B`V,3$@-34V(#<R,B`--S(R(#,S,R`P(#<R,B`V,3$@.#@Y(#<R,B`W
M,C(@-34V(#`@-C8W(#4U-B`V,3$@,"`W,C(@.30T(#`@-S(R(`TP(#,S,R`P
M(#,S,R`P(#`@,"`T-#0@-3`P(#0T-"`U,#`@-#0T(#,S,R`U,#`@-3`P(#(W
M."`P(#4P,"`R-S@@#3<W."`U,#`@-3`P(#4P,"`U,#`@,S,S(#,X.2`R-S@@
M-3`P(#4P,"`W,C(@-3`P(#4P,"`T-#0@,"`P(#`@,"`-,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(`TP(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@#3`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#4P,"!=(`TO16YC;V1I;F<@+U=I;D%N<VE%;F-O
M9&EN9R`-+T)A<V5&;VYT("]4:6UE<TYE=U)O;6%N(`TO1F]N=$1E<V-R:7!T
M;W(@,C8@,"!2(`T^/B`-96YD;V)J#3,P(#`@;V)J#5L@#2]#86Q21T(@/#P@
M+U=H:71E4&]I;G0@6R`P+CDU,#4@,2`Q+C`X.2!=("]'86UM82!;(#(N,C(R
M,C$@,BXR,C(R,2`R+C(R,C(Q(%T@#2]-871R:7@@6R`P+C0Q,C0@,"XR,3(V
M(#`N,#$Y,R`P+C,U-S8@,"XW,34Q.2`P+C$Q.3(@,"XQ.#`U(#`N,#<R,B`P
M+CDU,#4@72`^/B`-#5T-96YD;V)J#3,Q(#`@;V)J#3P\("],96YG=&@@,3,R
M,2`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-<W1R96%M#0I(B6Q62W/C-@R^
MZU?@2'967)$B]3@F3K+KMHEW8G7:SF8/CBS':ATI(\F;M#^\IQX*D)3D)'5F
M(HK"XP/P`>1Y$7PL"@42BET@,XCP#Q]2*J$@27.1*R@>@X^+WD#9V\\1]&7P
M\=-:PD,?A)&((AE#40:TT@D4S\%7MKY<_'++0R,RMBR6ESQ,1<+6<'9S`9>_
M\1"M&[;X?';SZ1(6J^OKY7J]7-WP;\6/A$9[-,JA4:!T(O"1)$;(A."0JTB1
MTW!<DM=?>9BP#=>LW]?-`Y>14&S@H6)M\P$NQ$*`BHS.1S]CU%I$VKFR*Y5&
M(H%$Q2++R)EUH;(QQ"AUSJY6M]>04&22A3R,\?&3M7R*6V(639Y.9J(I4[0B
M,[?54]L-L-J1I9C!%<$VK,4D1?C>5?5#`\N^/U:=M1XJD4$HA3107`21-><L
M?2'-C!T)2\:Z_KAI!BA:N#T>*I#Q)L3<K3J09DNK=F?-H:]T-N<P)A-&7\UA
M7\&Z*H]=/=15#Y<OY7[3/%1P5F+"T==`UFR)0>:Q?E-'!(4N8J'T[,),+HS/
M)C<BI:@I^`[(XV/;#'NTC*Z?ANKQOB)G*7Y46(ZW-30B3US:[4J91&@-.L.<
MJHDQ>F*,\MD_^WFQNOD`RQL7R$*\Y:"<N&%7*C.@$\3H:#AEGYWSX@_22\:8
MDR1&+0R8_>,_3>DP.C;NV\BGD<>66JPO]Y#DI(6%25/I"Z34E#\YID]:A2]B
M)>"\?4'26JU8&*NBJ3$O@KFHX6E5DSB6\/G?IFKN.49G6-4]N,4''E$MU\_U
M\#?/,>>5_=\1LV)VV#1.;.OH+C+$=@KQE)21E"&7*>962TOIG(WO/&)OMM+,
MO-[(\.=8'\^).(E*SA6E)3F\8V?;;5>Y+NI[:#D.FY@A/VGFP%/',WRMF]))
MU!239D\;]WH`K_G")6XCYP>>SF+?G;&*:*K9*]L)/JQE)UF.".ZX"P!G2QYA
M?E!4Y;&9(IBK+_U@^;KD,D?59EN7FZ$";C-R_Q<YPZJ4^ZK\TZ\?N<RP,!O"
M(UDW;C_O*VP@ZB*W40%%G3C<DCVXW=H-K9XBQ'E!5:7MP6W#SJK4A\J-%<RD
M,P+/]<%J'+R@P[>KW68%HZ'FN'&J!^B\D2=O8^CAZ(6VE3=;MM\]6A\-7+5N
MH_-A8N/S,,>9'KH$7?&82MJ2Y"2C)QD[WMZU3I3/37LEOE&_9$+'.GO7,6;N
MF'%(63?$!PM%$@E"\ALC%F("X._%.KXL`@DU!#)/Z<R*328B/%9CD:`CU,LP
M)\$N."_>C1@M<72A`@:139,KG['DK['D+F09.20I(G$-@^>$2B2$6AB<OR/=
M9D,R/Z5;^K]TRT[HEGFZY4BWF6W96[9EGFWXY!/9,B*;0E4DVT2US)[-%,#D
M;'?L_*>ZW[]2;+P=>S(XB'6SLWZ0)?C6C>"&NG6B#5+JM2/DHYP,5MO)CE\,
M^QK1]40_Q29.(;ZZ!ZMZ\$&T)]PZG4;SC)7SR4G)P-GJ8C1SC&:,T4\7Y6,T
M-D9"A&RNO>C.@TDH/FPT/"H;&-I)WBTJ6+2/]JL7KON^1L&GH_N.=P*WV+@8
MF\$*HR&\)+@O=%5P*X5I39B'%%-3Q:[QM/]TQ^[O.!R;K7?>36FDVX(+`.\,
M-GP?H?/G7[Q([\Y\>ZOPZ,9$5#;/Q0_!=.:%TZ&'9W=)]P[OE.X=@HZEG'US
MQQ(:Q8/V??^_NX']7B$$)65,M;WAFFY?X'Y3+VNMJ'-5@G,'KQSV<G'2QO\-
M`'J/DT0*96YD<W1R96%M#65N9&]B:@TS,B`P(&]B:@T\/"`-+U1Y<&4@+T9O
M;G1$97-C<FEP=&]R(`TO07-C96YT(#$P,#`@#2]#87!(96EG:'0@,"`-+T1E
M<V-E;G0@+3(P-B`-+T9L86=S(#,R(`TO1F]N=$)";W@@6R`M-C`T("TR,#<@
M,3,S."`Q,#,T(%T@#2]&;VYT3F%M92`O5&%H;VUA(`TO271A;&EC06YG;&4@
M,"`-+U-T96U6(#`@#3X^(`UE;F1O8FH-,S,@,"!O8FH-/#P@#2]4>7!E("]&
M;VYT(`TO4W5B='EP92`O5')U951Y<&4@#2]&:7)S=$-H87(@,C0V(`TO3&%S
M=$-H87(@,C0V(`TO5VED=&AS(%L@-30S(%T@#2]%;F-O9&EN9R`O5VEN06YS
M:45N8V]D:6YG(`TO0F%S949O;G0@+U1A:&]M82`-+T9O;G1$97-C<FEP=&]R
M(#,R(#`@4B`-/CX@#65N9&]B:@TS-"`P(&]B:@T\/"`-+U1Y<&4@+T5X=$=3
M=&%T92`-+U-!(&9A;'-E(`TO4TT@,"XP,B`-+U12("])9&5N=&ET>2`-/CX@
M#65N9&]B:@TQ(#`@;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A<F5N="`R,2`P
M(%(@#2]297-O=7)C97,@,B`P(%(@#2]#;VYT96YT<R`S(#`@4B`-+TUE9&EA
M0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#<Y,B!=
M(`TO4F]T871E(#`@#3X^(`UE;F1O8FH-,B`P(&]B:@T\/"`-+U!R;V-3970@
M6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#0@,CD@,"!2("]45#@@,3`@
M,"!2("]45#$P(#$Q(#`@4B`O5%0Q,B`Q,B`P(%(@/CX@#2]%>'1'4W1A=&4@
M/#P@+T=3,2`S-"`P(%(@/CX@#2]#;VQO<E-P86-E(#P\("]#<S4@,S`@,"!2
M(#X^(`T^/B`-96YD;V)J#3,@,"!O8FH-/#P@+TQE;F=T:"`T-38R("]&:6QT
M97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)C%?;<MO($7WG5\Q;!BF1
M!@8$+U5YT<IVLA>OMR3F5KMY&(%#$5D08'%`<_4=^>%T]VF0H*2-4W:)F%M?
M3Y^>^68U>K=:34UF5IM1EDW2J4GI'[Z*J9F[!7^M=J-W=[$P993EU,1R].[/
M#YEYBJ-TDJ89G2]'X_[S-/K9?IMDB\G2-DDVR6S9'O;MP7?)?.)LU3;F\3G)
MG#7W89,L;$CHY-P>0L.3)48A^=?JNU%JQF[BEGEA5N^A:<&:Z&N:S:%HE8QG
MI&A+9^E8%4V2I32^#WO,M&3!PAZ2!7UWR3BWIMV8CTDVG13]6L"1Z@DG&D/&
M+R<S&^,Q'`R9^[$][-B?A36S,=:^3\;3"0F+6U^36TM;F\>@NJNF;"&*W-:/
MA!S)K,<&L2.L$09:-;T)&_VE6)3X"J9JL*EK57RW#10Y-;9B49$7"HB%ISY)
M;2=VR0;RX0$NRYXK,]2ST'3D:A]UREKAW#GJ^26_.<+>AX1"\)",YR1``I/9
MA=E4-?EV2C+.2]5M!V:S$3:41[;=V4-%%DYMAY\0C6^PL#8??BNW^/;-$SX$
M)H4U=ZTJWLFQ*D9&%/V_W5^)K8V;WJANEZ9N(KYE#@AW#.]9D4]F`F_Q+9TI
MN.1+P$4V;]JZ;D\5F;$DJ6:?C$GDC.+LQ.AH#NS_C.S+27D=?"0<T!Y[\M%4
MC"%*-*6?#SUSC$C(;5V2P?<ATL:,Q<A9SU!>J.1R>P,Q/[`+CI/E:'$]N3'>
MG+9D%$WP3"^S/34!`M8F'A]CM:X\F9;-!WH)^J+Z9IAGSC+\+\[^%^<J=A3S
M1GPN;$G*&4IAWX7=(]6&6]R82VR)2A:@$F&)29$Z9HK<398++F3&#@"57P@C
M74+5;9T4E%2)BWPI+1"V<X)5(%]F3"4")_M#MX9.VN,N;K!`5UQD*UAG+I6J
MR,@/#L-#2\.9/79;^34?#Z2QL"&<N$BX>F3?<Z]AFEVK.)>#2Q?G<DAFE*.4
M.>+O5%><SY800W"4A8Q7^I0*9SG[#_;$,#3L?"9[LWS:1S)+!Z'D,(XICOG\
MA:_9.6/9V1!3[7:!DM^14Q2X1(KT$&K20'Q"\!05'U:CS%1F1&50S+-),:.:
M(/!,68&C[:/-Z!OI#E0J:`_#RBFFQ<0MN'+$#"=F:"(3-Z7@$6:(Q8GYV0S!
M-B%]9K]P[1+@X?9MDO/>,N@F_`1SE_!TVV!<-4<B!WRW"3/.EF@UMR=Q9/5'
M<-2KXOU)N'=*VU"Q@2N(\K$AX93\VGS`%_Y6#+<9M1_F,H^MU(N$49X3Q[-$
MQ>:NKIJJ]+59'9#3RM="#!%'#*2U4L.'H8$,]'(TY%"*%$/[*1ESBL+X/M2^
M([;XY,MC[0_F?7CBGIA).R3IU!=\5UU(FO!PJ=VS^ZZ'Y.?[%4.1&>$SR.-^
M]9<;LPK<NJ;V-X_?B!\S?E'#Y-U\20EGJ)W32W!=_7N(BI1AD)X;Q85!M#T_
M$/P*F)];I0T.'#4]MZ!8SU\KGD\HEV>1;G8IYREDFMLFD99%Z")04'GY+YQJ
M27'&2;@M==QY*3T"W`TQ'Z5F876)2%"8Y-NFG/R!B%K6&IR_EA8[+#Z)4J^C
M%HN-MEL90(%I`I`Y)JB[_$7%SB_N*,FNV8FY/;+\I;TQ1(&B8RG"E_88Y&=M
MNE8^S!H3.PR;V$$`7*5@&ZQO-J%405]P60@-]ZNA;(.CXFEFU]"'0:G[8);Y
MTM\W>#+BA[BZQ@>.#(3+V.R]'%8KZ(H1]<(C1+M4:71%X,N!SJDMW;!V\N+5
M!63#C$O>[HAL^5K`N63"G5,]CSDGQC_),(QE'W9+4\EMC8!AT'&)R7V,9>Q\
MR1VGX#"\V@HA9@W!F%,M3<`BXR/C(VTS$8%\A^#?S,&0':QL5.U6I?7&>!G)
M"74$<G&J]Y9N2K*M;:"^K<1,'9FHPH_KYZLPOFZ[:[K_<5]M!489?S('D1CB
M6>J/_.L[<\O0RFP32K3C%MU8"D_:,YHU%5[H<.4B*7"[$!F[)X@\<7!R>$O-
MW<1*FCU6&\QBBKSG^R0&9<):?-/AEO`,K73E[E1=_X@0LPQ9S+KW&(88\*'&
M0F2C%EU-1KPF,.CO21H]M[Q$3]EMS^5#RJ4X!."5-%UQ9"E>D37QO(YI/82!
MT34<C/B1PI(/;(I\-UX;019)WV+7(WYZG:JMUK:/@RI/EM0J@XVPHCU!)M7@
ME>E2D0=>.UO:Z_$2VV[KKX1B9/90[TOU^!&J<5E[P85OP/'SACF#\](A!^`,
M27:GV?1]RM<]FK"57+AMY*PT!L&G8A'@>`.KJBL1>9D,"H7JC4R*K]0'!4X*
MHS(T@V,&D&P5T4#>)JAIU[BDH#5]::DW<N\+*D21R6>HO45TD4'4?I9,GFOC
M!79[U/;D@2Q+=:/(S:/OK]-7^H(9QL%HU)2W=E#9X"%'-/:FUH[[%BI][Y5(
M*$$J2H-CP`6YCO9(UC!"J//0Z#ES[:XD00D6T#!]Q(9\%8#"W'IEJ_`H\^U7
MJOFJ+HY[\XN5SY@PDCNO^(_Z6\JT!][Q]QF@-UIU3\,"P91XDMLK"4UWHS>B
M_9\29A]Z.F$B+7Y)Q(2)^18SY^K$D%(4H?/X.):=+WWHV^)9M40]0TF<:YH!
M;2F:2@;**UO3\]L:(G8]10PD@)(OOI=*`#'V3O[O!E1?/?9Z",>;OK:WPYX`
M>&R-/@9[@%Y**5>V'=1YORB#FZ^"NWQ5B=?*/=9E>U!TLL#K=N7+OD6];'AG
MZQK#AF<#XXSV*[P;F_:(WU+;\=>:T<ODT5N.&8L36`9`L3,]%D1?I^D%=Z/M
MX]:VO/25_M9&N=W)=C\$M`*R\WUO>F-1&]/O-+I3,K!:[-+VU@A)#AH0.=&W
M-]U!ST)M--HH82$S4*$'UGW%P'-3I.ID'YH$G5E+]>7%\Q+EQ>#>*>U1L@.J
M<:`:;7<.+=8Q]'HBF1&-Z.W.(;).F82?F3E@Y2S^,G:419R%*.T)F!*L.3LX
M31S"[)$19TR$-69OMUPWO3CDX-![>;!R,*;$,]_YJ`WDH98%_VL7L,@-T0'X
MWF!*[NI3W.]G\J28X2TTM3AMXEXF0XDM5XN88GHE$09MG13\#?.=JJ`R8`EQ
M+,-[67NAUV/MD_Q5%>6QYO?$6:6YD[U$+4=YDL*$SC<RZL2W:%H9;>#ICT-=
MIU?-6%XCKG_P9HCF/TF`8S3R`_+PJUS;[NJJJ4I?FY\.+3UYIYP_OI7&]F`&
M$^;S7@9;:F-S.,)"ZEU;MT\R\\RW>B?76[Z>_<A,(DG@?2>,S$L+_MI4?*F=
M\?6'3X=#K#K2EYW%/93;MJW%E%Q-^13655DU0=3^O[?@J'U[WK^ER$BECG"Y
MD^1VV$76O\L7:+M4M_3X6'*C"7VI0YV\/0:WZO/;8\YO#Q1Y><460U57W?OZ
MZGLMMF_W,,IWJCV>>V,Y8)FW:$\N)=RK[ON+^>7*KHUT&-[Y);P%PLO`):_I
M?K_0Q\,<H,SX7>#25.8=^ED(,F(\%U)@2V$U<8`7S-6<>?`RVYB/D.N;$ALX
M^G,K$9\SF'CWQ/Q'-JT2?H-NH<E<&W2LY3CTQ[.V!9X40]GR2.5=_$C]+^ME
MD]NX$43AO4_1NU"`K8@4)5'(RL',PHL`!L;)9E8MDA[9EDC!I)*9<V3.D3.F
MZKUJJBDK,)`$AB7U7_5?==7W,(WS9LM9RS9RF[`;=J&)?IB\D-AX:%D2CHE&
M0<.LE(#C4UZ<3GG.4_8-5K'0#)/K`)SW*M'0PO@@X?T5A3U85QN;GC4XH'G"
MD?RL656AGSIB#I#("7$IGD&.(]9)/=N=V6.3CZUJ`H.I;JN:#56=1Q5V.LS8
MAWT@M*V2RM7L]6@3@DW0HXV'.X\XZPY;AG';*SYM)65K9\,B#RA8W;T#>N?R
M;3]649%F:4>::2RD>G?["^H_`+0HTKZS9XR!>T/$%PH*$I3C(+9,W2=3"2]!
M4,;S3KFL/U%XT`@JX!D+E@!X$5\6B1&<A$)R95@T]573#O1IF^O"U"3U1T/9
M`(TL52[4XPE!=;T3DONMX8T_!#"W."2YHR0*'1G\&*HWM=7N)S>YG6(*'UJ?
M`J2U44$8<5DP!KA9[WX`RY'4()L-.2+.""-;>L/Z_0%S3F'Y^R68F6?#OBW[
MWNZ``*4@C.XVY]P"#\ZS18\QP[JDK<(52@+<M[_SE^4MOPT]Z'TY`GNN4-W3
M;NT:?M/^5PZ7G>F5VF5*YOH2+X(V&A9<6`E*['=D81<P!JXC.9K'L[3%AT7[
MPX$58?&V12"^(L4E7KG@*K>26$-*M?1Y*0^.TRM])KB62;YC4P9TM]Q'(>'N
MS?6Z.NC8N[O@(QQ@4UHZQAWT@[B+)(!AA0^XCKI<$O#,?INNZ`-XC%/[*1G_
M^A8)QNSRJ?>AHAL`Z'/R\<CUF,?R*=CBKHU4CH$<7F.]%*.(5=GY*")2/?F&
M-96?VB-YL!,U&NKZ8XQ-X0(&Z7>3#S.=HTT:W6D;+RG<,ST*F_L:2S5[]7+K
M[!\F7<QFSD[YN'DFW)1!*_[D;MG;PDH3!ZQT'J@Y)(>G!G0Z)\PNE+H4>1<`
M+GF]K[*ZLG\:=]I]8]'5S6N[$\CF$-&O_9.JUBF]3X+W2F,N&FM=,M(DCP#P
M`2/5TZLL?[!9"C'<*#D0RF4%G6")&C0JJ6'O\;&.UB6"M`-'+^S]_:.,M%>W
MI-<5](A"[V(><LGPX@J\N+CIU?3D43`4\G#;6L\602UI*#3W)A'I]\K^,A`I
M078(57H_F2'09LQQ60+MZ(XF/DUVVG/^S73K$<9LIAH;7;J9_"U=/A?46[IT
MG4YGN8;E_=4,EZW;3OZ:/#Q?B6;2OO*5YZ)87%HLIWF!GNH;Q>`;.8_*/5&0
MXEHGA:XIT^?:6803^;@XBW+%Z;R7-%+)TA,O^Y`DW"D.\-&HBVM8A^,7\O;;
M/7YHM;X9N1?"<M*+.]/U"^H*"6=Z2'*X,$2N9^XJ]$B1N>0H[_4W#C<?SZFG
M*6=9F=&F=JB88`:33[K.MHFGQB--=0ZE,#[>@K-7_XW`WL!)*'MV<X9+3$Q=
MZ'5`XS:,;O'@AVY?4#BR,#+0DV3:9D0^PZ0B`HRP#GQO-&N(.*9`MZ%WTS#M
M-J?YLQ`W,\;-T*6NIIS,_:S:<HX<!G+++%/H@WL'M"P]A63!,TT-B!R#W\$(
MB/&T;;IAR^"=`X.^-==Q;NL[BJ+`4JYK79Q(+#:?);!K2QY#MAL16V\S])=2
M[RV7_Z^1($[JM@<&#TM@`D4V9!OGWA'/ON4ZO77C)TE"(+**&)L38[5\AD-0
MD0,[P44&7G.><.&?:6P$6,Y7@:B:DB#HQNP6R-661'K;LK&WKJP,_&CSFGK)
MX+>Y1(@+5)NM3DZVX/;O)?)-<L"S2"YX!<M0DG;Q#$%2TBM8A8+0*(94+(['
M65CE`)NBY)<&6U690]\O,',V7N6(EO5R@WJE(EQ3,Z90KVOH-!.<:UL@].9@
M"N%-E"6BX/^U-00+C;?<2&4];"NZF$)#$^:):'-EK_X<GB^$5+]A6#KVCC&E
MOS;/"O*P](QZ_'0P_./#@V0_L?9XM9JNUI(,PPS%D"L_)X4:6BYOQ&&*9+G6
M4L;"`@7Y-&,%;8ECS2-;;YACBJ7=-0AP"+B('PE902,6$I^^H<99JI_,#<=W
M++?.`T0\VUGK-_RVT-ER!A)@IFKLAP[$@<<@W39&%YRR)E[?R"7-LG<3^1^2
M"_DOF72JRTI*I,RV0=(NIT)NUZJ\F"`9;I96$.Q//NE;S!)E]0*.N1PZ;>N&
MN1V)_85Y)ZH""3P-4V)V,G"!S2R%)[6Y[L[O.9/+6=CEG'AHJCQTNL";;*Z]
MQDYWNL<T';,C4G>:AAB^`#U.#1(7(3RG9'=<J.+%'+`[6?-5:<<=6M@>3-"\
M:*'--]8XWYB)AJ,0.@<;9<_&EL4&]C5WJ9GVB&)#9>796(60O#6S7),#]>B/
MVF:N0:H`AXNO$MGB<_*,D'IDH/W*`"[;%TPKF2%JAG?/TCBD<[!%Z=)B>-LH
M#,N0:V>#=J-T8;%]'/!E^6[/K%&QI?3!'FI#$NE9=!M+,16_#VW'WKIVLQ.E
ML+F=5YX0RD(;<ITID[TON7T[#*[=LW!M70E"'.!Y,C4/^./#U=\#`()]/-<*
M96YD<W1R96%M#65N9&]B:@TT(#`@;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A
M<F5N="`R,2`P(%(@#2]297-O=7)C97,@-2`P(%(@#2]#;VYT96YT<R`V(#`@
M4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@
M-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH--2`P(&]B:@T\/"`-
M+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#@@,3`@,"!2
M("]45#$P(#$Q(#`@4B`O5%0Q-"`Q,R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@
M+T=3,2`S-"`P(%(@/CX@#2]#;VQO<E-P86-E(#P\("]#<S4@,S`@,"!2(#X^
M(`T^/B`-96YD;V)J#38@,"!O8FH-/#P@+TQE;F=T:"`U-C4Y("]&:6QT97(@
M+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)C%?;;B.Y$7WW5_"Q.[`UDEJM
M2_+D>!;)!LABD5$0!+MYH+MI23L2J8B49_P=NQ^<JCK%OHR=V8$!MTA6%8M5
MIVY_WMZ\VV[79F:V3S>SN9G2'WWJA5G-EY/-TFQ/-^\>8FV:*&=3$YN;=W_Y
M,#.[>#.=3*?SC=DV-W?\<[HRVT\W/Q6?RED]F15[=RGKR:9P)NV=T=\E46Z*
M="B9PI<;^F^Q9[`7RSDO6ETYD.BW!>G$W!_EN"EG3!V\*6?3HG417#LA]JXU
M5GZ95CYZ^3.80-HX$\^N.4#EI_)N,ZGRD6AB<1/^OX#5I&`L9)[T):IN(CTF
MJT)?3@\O^?WYM7>SXA?YJ9HT:H<`?2?E?[9_NYF:N]ED5IOM>[%OM>CL2WX1
M^SX0TY*8:'-1G,[$O"SLI5S2BIY,*LPF\WQL@AS3)NVQ1YA*K&7/YTLYXV4@
MBU1@ME[(6^,^8^^L+`>Y\X1+?"*KS'C#)+W7ZK4=191+GH+>>/]W^;X7,;>B
M#5D'4B.N,EAY*/Z++!P6,-12#%47WIPA-319<=F_JBXFBV5S;O\`F"Y[F"Y@
MQF.YF*SY!E8F1N+BM<=:0+)D;,HISG136<A8K<"ZV_EON2:J*Q9@T?-HOKQ-
MK,-P6V8:Y7;R\0E.:F5U4MWPB0D<JES";@"?ZO9S`8/Y1G4VD*L\S=[HFS[C
MW)R4/^WCSZ7P3DH!T/<,Z04A2%;[H91H+)X5(20,+5[->HMO8/%'QV%<D0/C
M/DB6X-\IR*9YQ*$1-&J,K`KVJ00>[YEHQ6;=Z9_$2J<`*A7`44=?BZQ03Z?8
M9E14@-=*X%5E*8!754`1'XT*P.E8'X-'S!F%0M7I.5OF#$(1#85.4*LU!WVL
MRKCW4+4IJYY8<L?FU:U#$*]ZD]8PZ7WCDA7.FGS<L#LV`KT-H##3!2>S56%Q
M;@1`*SVRH,-1%#JC$@..#*.P(TQ.5H8<V%^6]N&:*-VN^XLE69*L;U0*_S,3
MD4T+:.F&^NGB&626PB3B4C%\G<]3EH.+8KRZ.,&;R/CL#E&F15"<->9:O,RG
MD=%?%[@/*"M:+7)-R\7A89#33UH?4BX,3C"9]I#`045*GE$NPJ@R434S6AAP
M`:I:P*(K*?W)N,2.9#DMR4955B%:I48ECK&9RRK.DU59*MDPYO`<FU"734S7
M88$^#*N<A%.N\C'?%L?)HNJKW`Q&;EUR$E05BBSE?2=IOD6`UW2[&-,'AA@3
M*!G?E!<<816*>%W@O^22BLVUS-[+1[IX!@6CR[:Z<""/E$CS#A6Y_R_*8I$Z
MG;D^JOMJS5%<JUKP7G="9Z`UEVMN?J3*U@0TB<*]S3<C5Y*^7J3D8L+@18F\
M^O9W,$PM3#MLOY*;P*?F5_'ZE@RWHH[!1#C_JY#/`![2'`:@RLAA/4=$YIY6
M%''?`KEAR"CLFN`'FZ.8N`Y;OH@B,WL5:HY;.=;J$8'I/F._<<.8($_?_H98
M\22G2+D;'9AX*B86`%==EECAI>1YL=E<;29/>@AR?"KOEOWG(`6!LL6Z3Q9Z
MI/RG1V%S%_/^,C$/]G(T_W`[V3L<C^'66'-QZ>!EQX+GF'O<"GM5<3Q$PG8B
M5J$C>K:(A&ZZN'"-YCYB'4-SX#!?26^.1MT/'SY;Y(=/UWCXO^A6[@I>ROF,
MT$E07$GO>(<6CA?A<FM^I$=RJ^CC"\?&@HQ=T=$S%M8?+'=80D[CP,4U*5P4
M0;S'=IW2+7C#DM]@S</QX`^-99M$R''V0LW./[V\GAOA.V&BFLE%W)3S*>M;
ML;Y*<CQ&\YVJY,Q?0SP?0&R/Z-"K+SKT/K;4`-SL2JL[1T!3IU02UH-W703,
M$0%S+;5KCK2CD**[L"T8_0YZ-E:^U^CB&S($P6!7MM8+@8OQUH"5FE5A/,MJ
M+PEHCNA?%^`E%U%3+4F'!@C<W.M/+3U/&603"_)/(%01G%;Q3E5!;'7WA;'>
MR$217"3!17[*R4$2D1^&L%8P-ZY<^JA3&-4^A#)$/;D\9?4AK\16J]@)I,.9
M1:>WT4B:4P>J[>C"&,=7J!K=$&MC=[?4PF2ZA%D\1FXD,T\X'T</[2PR+);S
MOEAJ,M\[OFHAW3+A(6*UD^JP9TF$?`QWBZ(U.-65.Z,2^5:_,E01="88VN:"
M9!W/%NQAF7U0>%K=E!<*ERB\X)(U*'+B(ZN"K]#G*)P6"P/%'5:[,A<0@J/O
MU`4E^B>'^T=L:?@N%3P1^BVET$*541;!LO`.Z^2Z1^=23<O`*P(ZIX5TQ-SK
MUSR54;C(%,1N9,PN9<[E(S(93;FR\ZMLB!27?I,%IK-U%B9;J#PT_[66WP$H
MT<`HP]BZN!6L0U;;L[V`:J)R^9WB<88:KF3:U$^;B^&E)W!A(93Q2FZ1<KHL
MXI!+GQR4)>&*G?3+X)>!CCQCPI/QU'"^:C]^0HJB'BB@\S#C<(E1BZ[&V]6#
MS'7AJ%5?T70%-=J"WL^$G#WXHNL3XS??JA7??A1>+D`;SKZ4>,&=5'B/Z;ET
M&R(L:X30U?2BS;:)'&GY$&_J>J^1M>H>A-I*B!-6PL1#&3<'`KY:+ZFX?+!"
M5R^'K;MHP[N@E8"DEIEKA0&L*G9"9Q(V>3ZZ-9?<`S,!(X&/&`O5F[RC/1D1
M5Q@1*P%6G1<@5[&<A$1#N"%K%?&A8,>M096(;U?<66^A#2RT19.TE\SA1A"I
M!"):EZ1$=7YDTK-\Q1,KR9]H)S7U5A+8FP$]2!SH$V3ZH8Q,JN.)A0[X'T`B
MQ:Q3Y>PXZ]>=XM221O1JV@&*^[DY%"[M(F@^LH>!:!76H?;5BS^Z%TCE9OC-
MVOPZ^S74^B*\V9E\D\8/=TLUNXWPZ"?F1XH.J5V,'[*6Y`(^I'R0%)LR2C&G
M]8UK.RK-4%UVVG3)2;)K[G9R(I+U(,M2NN%VO/`47Y*-*+/+UW#<%[9!(`=-
ML\.,935[:EI]S"]DO1G6XP;_#=#%<Z",SG`PZM&]\R9[FCT0/F:`B-]1V$Q,
M`)$"!B0XVU.95J19.'&0V3I\9T?RV[V<ZVS(B2FA<5>HC?$*W3IV;]`-NB'Z
MH<YY[U1)\!B5KY#")_@A/L-0"C`Z0NC+[Y3:IZN77DW<+0[H/$'&R?64NQA*
M'UITZ/=5>#0J;#.LGH)`_D==<[Q2?RDDT;3@_H*RNTEJ[:`J6K[QE3YF@$JQ
M.;7&L(=57K/KT$S-)D,K(VY8<E.O3)-<:PBJ0]B]FBX.?:]^#N@\YUSDI!GG
MK@W=>9XKPA6-/!X?/$ZE6S?V$7/$-9F9_)CJ>#2`Q9H=6C34V%,N@$SS>OH8
MCCR-S5.*S@M?&WITB-"K!IW*/!=.:CV6>.ZMCA:<G]>CT2H/`<LO^KE5;[T:
MUFLM%R>J5,@$7'<`MLFLP)9X'_O<$ZR*G,9Y!\P!]#$9Y!SE3^"Z"(W#'MC$
M[ROXO3NB].$C6!Z'Q)#96Z+.]X&;$MTSQ+GAMBZ,GND#\-&ZNND4CU*OJ=OL
M*HZDU!6YD,DF9&!*K?<>JC00&7!1LMWU0U,O>U,O8.K[ADJ4>'J!=G2A/2]Y
MC44MBX_1/(II**XC:RAMY$*B@?][$.]$5Q/`1.DSG,]*H$=4<M<:<6M!+!,&
MO9)[4MD6:RX'U!Y?W*+47#=$D:`]RC(32*O(1PR+):%1.?8XAD:-G.T-*)73
MRCVMBC%J$S7%D)1;GJ^/>AB;J#^U.QVN,(H19O4(@T_4@>SM$<F"5I.T"#AE
M@3HXO=5XO1%/]P!6$_RM^9[?5>=H:":8<U;%#T+R[Y)[V`_?_?%_C%=+;]M(
M$K[[5S20P\@+2V/JK<W)F\=<,L%BXQU@,2>:;(E<4R1'%)7XWV]5?54MMBTM
M@@"1V55=KZ['5^[A@QQ\D=U&D614;`SUI08DPILX_Z$P_Z73G*9!J56L]>NU
MVCQUHK@VLD8X4,1M6BNC]$QX(0]5WYGB`A<A/Q,#"U>DW47\]/:QGCSVU-KE
M^"-'_#,N"QK*N9/?1E=;^:">V`AOBU.LK42B&2]-GIY*I3A;>(4Q%\9>G_^(
M=W_1+.#4-SV@N.8$FM?OA=R_5UOTHD]![>Y</DP/NXLO9%/3$A>0=ZVV`$"/
M==/A,2+7V)M>$[,+D%7S_D^Z#]KSK>@X6BJWB(529?D2AE[3.A-^S6V]=$>J
M:/;C"C+\`K/S?\%BT-H];*OE19RZDU\,@4KSY#L5@5P@$!(7(^YWHM%U#6A]
M6"'D46D6#,`[F=1H.D1P8+HY5^`*2:;[;(DM%C_4\)'[8<]U+3Z;O->=]4B-
MJ$AEF^6!RHO+@4WABL(<SE6FIX27*^RD'>*D&:ZS6#LW(TT#>)+`$U90*)WK
MD`FURCJ:T2K4@;Q5JPH/,:AKL@*]:3/9+-T]_9,_%G,WFZXG"QI#>\1GNN!0
M234J<OK;'U3.]_QFW>V8>$<]M>0I[YLO[/A20.0X.=-=2NV3@#>Z,S?VG9&.
MW!G67#SC1-:.G,,GO*GRYGXOXC<`A)S/XZD45T,U0<E#P^9K<TKUFDHT!7<P
MY>&WV_&*CN%S,A6/Z6>ZF;*S,T9/<_99.M`95"<*JM^Y=_(8[^3^KX^/"5UW
MC]N;))G0H!9I\A<'\'XZ85Q.PI@P6=Q/7:?RIHE%<ZG;SX>T)Y.7E'ADOF",
M#PUM=D#"!VQOM1*I-<M2XCXS2"/Z=YQ+6YB-#OF8)7UIFF=<#]?<-[1HT93*
M_ZI!]T.N43KL<(@H?7J\25SI;L0E<F[MILO99,[=>NH._F9[\X]'"<7\:BBF
M:T(*:^[C>W+UL2@[+B#63H-U#0@OMHC]%56(FH4F`.?*6GFW&J(0&PG`6I!!
M.*(4ES`P#J1`E.0\@M:9//#J%R<7;QS1H>I3X25WJ(71"MA:UBX^,,/WT*V?
M:<T&--LKS/\4)\K3*YO<-Y_U`R_+6WL\Z5`RE3$\[S$[IU.>GN-S:^._5MK9
MOI1'3GX&LPG=WZ7V2;GV+[_%AV&#O7N@MDL&)YO-X@YUNPDHG/N<E-A9'+G7
M:NF5=5:V:56]N*,)W0CB[`^T(Y65V?&:GN%W#RFMZO+*Y)6I*NLR2RN[:SK3
MJG/;H3@E,.S.;@F`'O1""KDG/PC</)F=`R=5#[S--U`H*P&N&UMHD$I;G)<5
MP4;W%61)%N+Z>""40W-YYQ[:MBHS$\+1QFV"<V+AUX\/!-U@+"@J@UYXI+<*
MJ`Y?X\2L^?<$9]\FU`T(9*=R3"9^E`"L1K*P$N-#KH%EL779'97.\3`U3&IJ
M\,.\U>@S!JL8R1XY`Q<7<FX6<DXAF\@5%.9_M/P.R.Z55,:8X6T.].Z>?(T<
M)'RH')VPNP8<2I3WU"/Q8&H"4P@\>8VB/6""4I^?%4,CEZY(F/&(5M64QDK_
M0>.%2'T>:">[F>[\&*KM/E17KQ19GNS!I09F?95R<I!KN=^1V^I&?)GRY$J"
M)NLP.W0J\5,Q!G^@EI",?I?Q__%V-N*TXO,)*R!UCP6U"Q[^WG6*5(20ZJ\/
MY@K,K_48O!2O4U.%Z#[7M!"2I91K.HRX+OKZ&O4`H269U3V+0,(U/4VX`T"+
M6G)[3V^@'\Q+@);S#3(:_"JYT*N8![B;#=UJ1.?:[`^UM9(&3(JRPD4>LX07
MPX=7,CI+^\YS*\,+IE%.]]27]#4U)9##O>:')?:=:ST$:%8W8,"9I8N.?P:O
M05M1^I-7!GH@+9&C2;%:&B;>Z\SRIDN$\!A9C*1;YZ5:LXT*Q1RJCVZKEU21
MVN%X]1,[]&(?Z>L'^J:A^D+ER&?7GV-SK;F$K%?\R2$<+]"&N:\U@,5ZN,>/
M!7%%+S&>:@H%IG-`&5=JPJ_ET8A(+2OB)K#B<YS@18BG5#W4XJG<GUXH,\*=
MY>@\)V#@^%YZQMQZO+:FH($1"_\:8H$A:E5Z-/`L5U0Q(,MJ%$PG+R=2Z5<'
M7(BD`@-&1"M,.0A?C`R]4(:I#P?#,V-KQK2G,BZ7KB[Z5^:O_$T]_U3Z[QU"
MOL`594#YK`)*2FMJJ:\UN[03R0J;5@!-<S/1Y9'%S#74#EX#FI;-5)"7'1+,
M.1R_J(RE28..^$[7FN^PK[F2N4D`^PL%^UN\77^K+X</@LL$]&A4GOA1$RB7
M#1#0AQMLJEQ$H"[^E$I&)C(F:R-V7;]O(P'421D7U=I,A;_KG_[KL^/M8O!J
MLM)B3]0@E=WS\)(T;+Z3"I>TZK,"#T,G6EP0\=N0@SR+M?V?/'T[YS`NI%5?
MGQ?2[.]TXKV@',F8KFCZ*G=U/$-<6Z69CCUR+N_].3MD!I+\JN0F0O%5MC!^
M.KNH`ZBQJSR5=,ZD*DA'V!A?H;Z#&T.CO`U@G-9D0S2);9Q_3E^/.U;<N4A8
M05423;15J/X%HKJWZ#%XV!72AT-28-P-X.X"_1QE)E_)/6I)][?P\/&A=7B,
MQ*G.K(4$;<2C1Z7+7)PRVLBJ/O=W:LV3Z#';TJ"4HH0W#;2JW(-0\JX;[`Q@
M+.@5LTS^L?!BR#:B5E4CS6"MT:EWS/3W*$+*$/N^MW>5PQ=X7%-AJW=4?"S)
M0D^]KKXV]I981VA+@'%S&+>6.3)3/(R_CZ"GH!-48PB<ZJED$\&@8S,,Q)S[
M].>/#W=.9:AIQ"G&+:B%=KRS4`_XU=0+^0"R2]LV.E#K3@2%E%/-?J.677H;
MKK6$:Z8),D=M)*-G[ZJFWE$`KTRUT&27F[![\,Y:I/7PI129D7P)R!(X/R$T
MD1W?X\:P@)#&M""`^;B7KUIIG,IKAO$G7S6M``"<-,JN)LBSRX8K]]NT+KW>
ME0.5_C*H'%(9X&D0X_8B1]F%[1GF^Z/KFJ8V1<V`P[7G#P:)`<*KV$;C\>1_
M>JU37-E<1'9^&_`C]ITW^Y-MA6FM!R&'`Y+^Z67NO<L*0J^>4J.CIE'X`%<C
M/B*IKMI_5TQ`#N0*5;.CB[&RPM-G+(&FNY0&0.3W*I4GX\_FXZXYB7&C6I,H
MRI'HZ7>T(NJYUAYX7>5W93>D3?3V?S#HEF'019F4OTHDO+B!HY%6PD5H-%-H
M]+T,EZ$GEJ4B>(;"2:2W,I$#/.YB(UX/IDW(,L6EC!(%U,J6A9=<R8ZUU3\%
M;MCY+3\!=T4V/#EO?`>#S7)H<X@7`BT_J2@AOO!1O#V1\4,MWK3(-1HQS#!8
MGE:CK3%NI$=#-Z'9P0S%=B"EQTQJP[E+2503R?6!ZB'=/(06:6$;:6$3Y?WT
M@US)?`MHRN`/&%*_"O/1_SA'EJU4P_Q??1G'+;_6'-[D>4B!-]UKL`V1"N6B
MY\1YYS-Y<)FU*[N&#^N65:I-7+\9$E]*;4M'D==;'G>#2K(<YU*+"K%DF(RZ
MT"ZJ*TE?[:SP`IBP?G]9^S?UB#O'=9\N]I`_1Y]^4&.CKN8^-.CZTC4PC>]<
MF&7#LIL/*@Z6/!M#W;CFJ2IWP[9R<0JT/;%EE-!]F\>!L;D9S99AFP']5%*W
M2&N;:,J]O31:&4+'2:%6P!7U<3#M.`_'/SVEABA;)H?-#/3PO0V*8T?Q+*S'
M%SZ:`$/4DMC$&W:6F<TYG7H5/2[!3=X,PS23H6,3:!N)PM3;0Y)9R*_37#)#
M[_;1;.LOC^&3P!1FZ,06IQ/69:6R9IAN?12/;F@X;SZO;C=OXL3'\E9S2D\_
MD??Y]'CSOP$`/P':D@IE;F1S=')E86T-96YD;V)J#3<@,"!O8FH-/#P@#2]4
M>7!E("]086=E(`TO4&%R96YT(#(Q(#`@4B`-+U)E<V]U<F-E<R`X(#`@4B`-
M+T-O;G1E;G1S(#D@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=(`TO
M0W)O<$)O>"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B
M:@TX(#`@;V)J#3P\(`TO4')O8U-E="!;("]01$8@+U1E>'0@72`-+T9O;G0@
M/#P@+U14,B`R-R`P(%(@+U14-"`R.2`P(%(@+U14."`Q,"`P(%(@+U14,3(@
M,3(@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S$@,S0@,"!2(#X^(`TO0V]L
M;W)3<&%C92`\/"`O0W,U(#,P(#`@4B`^/B`-/CX@#65N9&]B:@TY(#`@;V)J
M#3P\("],96YG=&@@,3(S.2`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-<W1R
M96%M#0I(B9162V_<-A"^[Z_@D2PB6:2H5VZQG:1ID,*(M[W4/<A:VA&P7C62
MMHG[Z_O-#"5[':!`87C)(>?]S7!TOMV<;;?6*:NV=QNL&?ZP>%NDC5.5]6E>
MJNW#YNQB*E0W\7V6%IE34[<Y>W]MU?VTR=(LRRJU[7AG"[7]MOE#OQM&U1_N
MAO&AG?OA\$IUPV%NN]G8/*WT:_/G]I=-4J254XE-2>A2%+E%D1,]E\/Q7GUJ
MNY_;>1X.ZD9_.)BDT7\;6Z9>AVF&G<]AST:F&\-ZK4WS%WKSFO6*SCK+$E.F
MM?;&9GHAZL(T::.;1GRS=9HWITJL7:.THNG78*HTU]],`IM63R9QB$X]A)W!
M0:-[0PITBU1\/?8CS($['H;I-0(;'XTC%>KRN-\'Q'=UO-WWW8\Q_>C.:4RV
MDC`*BJFP,::,8RIJUL'P$70)D'7UJ397DK:$0?"B\\)XZ-CWA[YK]^2[UVH[
M]NL>^)HB+?5@<I"$-).]H5N`U9D:V6@I7*?W4>JUJG%<Z[),F+MLF,L)50A5
M"`BHSEJ*\Z3RL'GA>_/D>[76'Q0VP")N`C)AX3,(JP],W*&2D/K!0++10(?X
M'DSB";)9.`?F/*A)Y(/Z1FP6D,LO$RDB1J![/D.A1R-=V@T/*4>"?#^K2/&T
M6$L]^OQ^(-NHA7E0OUV;)$\+_4:65[&R"-SYB["%P\+.1;@(7P`PV0(VV2#U
M)!Q5"OM1KG:1E3F"$!,EI-#I@H$7#%!))5<0;PJOBL:ECMZ'M;"6:'A79J7$
M=662"L@?&=IQ0F7FD6BY<7+@0=3,=431(T0Z"&H,7X6S'T/D?0`0GH(7D:1&
MV8A.-=S%RHS'BY;KT$7AZ$,_]R'*O,5-KK_S>??EA5?(5Z[O10LPK@%`8AU`
ML5YW?#`_&;5-[E\]=UT$>XY*K$F$8WN8U:FIZ,Q._-N+^X],J*Z54^$1/W:G
M(?91?@Q_#>-,&60_;X.L<BN.B%.'9S'MXN/`Y5F62U-YMS:5C8_Q<*!0'761
M1ZO,_#NAG)"8V_!%+EOCN.2`.;48OX/JEK*,#5X[)R7+UU$DJ&/4O`NCZ.N%
MX5Z.XVU@U3LDF2TOTE0:#62.]-+4"[/P#)13IJ-'BP?M(A.9G_LSC!+@/V&W
M-D&<DBY/LZ;T"NV8^\:OHZ%>1T/,U9M]1V/O`YX"#Y=HZG4O.TIR[C)YR$3N
M1G\&6GAI[I<\-.C%B=7,J!P^G>-4H"E5^4JA3GW9-(LW9;Y"E^=QCO+SVB(L
M3P\`M;K-ZDPW9R#RC'XS1V?>%[!W_DC[,M-T,?$0H9UZSVJ.1N98I7>#^AAG
M0,:H5_P?V,ZX3"YV\;2Z:,9TZ^#A6=IRC91H<-LPV!`I,"]@%$7,#PC-_!Y/
MEECD17V,&XQ/,;C]Z<4WB8LYV$)/H?MY'Z#T>DS5[WV'#D&#7%&6R>&$'`B3
MV.`GMN17YB39@)YACGWR-'QLLR3;<R-0PY-KDFP+"T@W'5#":5U27B*_,>7$
M)9<3>K2(>[S=-,]7=3*^D!5@RO6.'CMO16(O3/^1?>L7E]</&?HNR^%RAO3G
M#J8":;?X4L.W`H"'`SP>9Z'#G7$T,6#<93#-#TPK(I.Q%>$1.>7P_T#SKI>T
MQR\'(8#4)ZF07)]<WS,1A!`S;[>;?P<`EOMT]PIE;F1S=')E86T-96YD;V)J
M#3$P(#`@;V)J#3P\(`TO5'EP92`O1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E
M(`TO1FER<W1#:&%R(#,R(`TO3&%S=$-H87(@,3<T(`TO5VED=&AS(%L@,C<X
M(#`@,"`U-38@,"`P(#`@,3DQ(#,S,R`S,S,@,S@Y(#`@,C<X(#,S,R`R-S@@
M,"`U-38@-34V(#4U-B`U-38@#34U-B`U-38@-34V(#4U-B`U-38@-34V(#(W
M."`R-S@@-3@T(#`@,"`P(#`@-C8W(#8V-R`W,C(@-S(R(#8V-R`--C$Q(#<W
M."`W,C(@,C<X(#4P,"`P(#4U-B`X,S,@-S(R(#<W."`V-C<@,"`W,C(@-C8W
M(#8Q,2`W,C(@-C8W(`TY-#0@-C8W(#8V-R`P(#`@,"`P(#`@,"`P(#4U-B`U
M-38@-3`P(#4U-B`U-38@,C<X(#4U-B`U-38@,C(R(#(R,B`--3`P(#(R,B`X
M,S,@-34V(#4U-B`U-38@-34V(#,S,R`U,#`@,C<X(#4U-B`U,#`@-S(R(#4P
M,"`U,#`@,"`P(`TP(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,S,S(#,S,R`P(#`@,"`P(#`@#3`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`W,S<@72`-+T5N8V]D:6YG("]7
M:6Y!;G-I16YC;V1I;F<@#2]"87-E1F]N="`O07)I86P@#2]&;VYT1&5S8W)I
M<'1O<B`Q-"`P(%(@#3X^(`UE;F1O8FH-,3$@,"!O8FH-/#P@#2]4>7!E("]&
M;VYT(`TO4W5B='EP92`O5')U951Y<&4@#2]&:7)S=$-H87(@,S(@#2],87-T
M0VAA<B`Q,3D@#2]7:61T:',@6R`R-S@@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,S,S(#(W."`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`-,"`P
M(#`@,"`P(#<R,B`P(#`@-C$Q(#`@,"`P(#`@,"`V,3$@,"`P(#`@,"`P(#`@
M-C8W(#`@,"`P(#`@,"`P(`TP(#`@,"`P(#`@,"`P(#4U-B`P(#4U-B`V,3$@
M-34V(#`@-C$Q(#`@,C<X(#`@-34V(#(W."`X.#D@-C$Q(#8Q,2`-,"`P(#,X
M.2`U-38@,S,S(#8Q,2`P(#<W."!=(`TO16YC;V1I;F<@+U=I;D%N<VE%;F-O
M9&EN9R`-+T)A<V5&;VYT("]!<FEA;"Q";VQD271A;&EC(`TO1F]N=$1E<V-R
M:7!T;W(@,34@,"!2(`T^/B`-96YD;V)J#3$R(#`@;V)J#3P\(`TO5'EP92`O
M1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E(`TO1FER<W1#:&%R(#,R(`TO3&%S
M=$-H87(@,3(Q(`TO5VED=&AS(%L@,C<X(#`@,"`P(#`@,"`P(#`@,S,S(#,S
M,R`P(#`@,C<X(#,S,R`R-S@@,"`U-38@-34V(#4U-B`P(#4U-B`U-38@#34U
M-B`U-38@-34V(#4U-B`S,S,@,"`P(#`@,"`P(#`@-S(R(#`@-S(R(#<R,B`V
M-C<@-C$Q(#`@-S(R(#(W."`-,"`P(#`@.#,S(#<R,B`W-S@@-C8W(#`@-S(R
M(#8V-R`V,3$@,"`P(#DT-"`P(#`@,"`P(#`@,"`P(#`@,"`U-38@#38Q,2`U
M-38@-C$Q(#4U-B`S,S,@-C$Q(#8Q,2`R-S@@,"`P(#(W."`X.#D@-C$Q(#8Q
M,2`V,3$@-C$Q(#,X.2`--34V(#,S,R`V,3$@-34V(#<W."`U-38@-34V(%T@
M#2]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG(`TO0F%S949O;G0@+T%R:6%L
M+$)O;&0@#2]&;VYT1&5S8W)I<'1O<B`Q-B`P(%(@#3X^(`UE;F1O8FH-,3,@
M,"!O8FH-/#P@#2]4>7!E("]&;VYT(`TO4W5B='EP92`O5')U951Y<&4@#2]&
M:7)S=$-H87(@,S(@#2],87-T0VAA<B`Q,C$@#2]7:61T:',@6R`R-S@@,"`P
M(#`@,"`P(#`@,"`S,S,@,S,S(#`@,"`R-S@@,S,S(#(W."`R-S@@,"`U-38@
M,"`P(#`@-34V(#`@,"`-,"`U-38@,C<X(#(W."`P(#`@,"`P(#`@-C8W(#`@
M-S(R(#<R,B`V-C<@-C$Q(#<W."`P(#`@,"`P(#4U-B`X,S,@#3<R,B`P(#8V
M-R`P(#<R,B`V-C<@-C$Q(#<R,B`P(#`@,"`V-C<@,"`P(#`@,"`P(#`@,"`U
M-38@-34V(#4P,"`--34V(#4U-B`R-S@@-34V(#4U-B`R,C(@,C(R(#4P,"`R
M,C(@.#,S(#4U-B`U-38@-34V(#4U-B`S,S,@-3`P(`TR-S@@-34V(#4P,"`W
M,C(@-3`P(#4P,"!=(`TO16YC;V1I;F<@+U=I;D%N<VE%;F-O9&EN9R`-+T)A
M<V5&;VYT("]!<FEA;"Q)=&%L:6,@#2]&;VYT1&5S8W)I<'1O<B`Q-R`P(%(@
M#3X^(`UE;F1O8FH-,30@,"!O8FH-/#P@#2]4>7!E("]&;VYT1&5S8W)I<'1O
M<B`-+T%S8V5N="`Y,#4@#2]#87!(96EG:'0@,"`-+T1E<V-E;G0@+3(Q,2`-
M+T9L86=S(#,R(`TO1F]N=$)";W@@6R`M,C(R("TS,C4@,3`W,B`Q,#,W(%T@
M#2]&;VYT3F%M92`O07)I86P@#2])=&%L:6-!;F=L92`P(`TO4W1E;58@,"`-
M/CX@#65N9&]B:@TQ-2`P(&]B:@T\/"`-+U1Y<&4@+T9O;G1$97-C<FEP=&]R
M(`TO07-C96YT(#DP-2`-+T-A<$AE:6=H="`P(`TO1&5S8V5N="`M,C$Q(`TO
M1FQA9W,@.38@#2]&;VYT0D)O>"!;("TR-#D@+3,W-B`Q,34W(#$P,S$@72`-
M+T9O;G1.86UE("]!<FEA;"Q";VQD271A;&EC(`TO271A;&EC06YG;&4@+3$U
M(`TO4W1E;58@,3,S(`T^/B`-96YD;V)J#3$V(#`@;V)J#3P\(`TO5'EP92`O
M1F]N=$1E<V-R:7!T;W(@#2]!<V-E;G0@.3`U(`TO0V%P2&5I9VAT(#`@#2]$
M97-C96YT("TR,3$@#2]&;&%G<R`S,B`-+T9O;G1"0F]X(%L@+3$V-R`M,S<V
M(#$P-S4@,3`T."!=(`TO1F]N=$YA;64@+T%R:6%L+$)O;&0@#2])=&%L:6-!
M;F=L92`P(`TO4W1E;58@,3,S(`T^/B`-96YD;V)J#3$W(#`@;V)J#3P\(`TO
M5'EP92`O1F]N=$1E<V-R:7!T;W(@#2]!<V-E;G0@.3`U(`TO0V%P2&5I9VAT
M(#`@#2]$97-C96YT("TR,3$@#2]&;&%G<R`Y-B`-+T9O;G1"0F]X(%L@+3(V
M,B`M,S(U(#$P.#(@,3`R-2!=(`TO1F]N=$YA;64@+T%R:6%L+$ET86QI8R`-
M+TET86QI8T%N9VQE("TQ-2`-+U-T96U6(#`@#3X^(`UE;F1O8FH-,3@@,"!O
M8FH-/#P@#2]#;W5N="`Q(`TO1FER<W0@,3D@,"!2(`TO3&%S="`Q.2`P(%(@
M#3X^(`UE;F1O8FH-,3D@,"!O8FH-/#P@#2]4:71L92`H1F]R(&EM;65D:6%T
M92!R96QE87-E*0TO1&5S="!;(#$@,"!2("]&:71"(%T@#2]087)E;G0@,3@@
M,"!2(`T^/B`-96YD;V)J#3(P(#`@;V)J#3P\(`TO4')O9'5C97(@*$%C<F]B
M870@1&ES=&EL;&5R(#0N,#4@9F]R(%=I;F1O=W,I#2]#<F5A=&]R("A-:6-R
M;W-O9G0@5V]R9"`X+C`I#2]-;V1$871E("A$.C(P,#(Q,#`Q,3`T.#0Y+3`U
M)S`P)RD-+T%U=&AO<B`H06QC;VX@3&%B;W)A=&]R:65S+"!);F,N*0TO5&ET
M;&4@*$$I#2]#<F5A=&EO;D1A=&4@*$0Z,C`P,C$P,#$Q,#0X-#8I#3X^(`UE
M;F1O8FH-,C$@,"!O8FH-/#P@#2]4>7!E("]086=E<R`-+TMI9',@6R`R-"`P
M(%(@,2`P(%(@-"`P(%(@-R`P(%(@72`-+T-O=6YT(#0@#3X^(`UE;F1O8FH-
M>')E9@TP(#(R(`TP,#`P,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#0Y-3@@,#`P
M,#`@;@T*,#`P,#`P-3$P.2`P,#`P,"!N#0HP,#`P,#`U,C@Q(#`P,#`P(&X-
M"C`P,#`P,#DY,3<@,#`P,#`@;@T*,#`P,#`Q,#`V."`P,#`P,"!N#0HP,#`P
M,#$P,C(X(#`P,#`P(&X-"C`P,#`P,34Y-C$@,#`P,#`@;@T*,#`P,#`Q-C$Q
M,B`P,#`P,"!N#0HP,#`P,#$V,C@S(#`P,#`P(&X-"C`P,#`P,3<U.38@,#`P
M,#`@;@T*,#`P,#`Q.#(P-"`P,#`P,"!N#0HP,#`P,#$X-C$P(#`P,#`P(&X-
M"C`P,#`P,3DP-S<@,#`P,#`@;@T*,#`P,#`Q.34T,B`P,#`P,"!N#0HP,#`P
M,#$Y-S(Q(#`P,#`P(&X-"C`P,#`P,3DY,34@,#`P,#`@;@T*,#`P,#`R,#$P
M,2`P,#`P,"!N#0HP,#`P,#(P,C@Y(#`P,#`P(&X-"C`P,#`P,C`S-3(@,#`P
M,#`@;@T*,#`P,#`R,#0T-B`P,#`P,"!N#0HP,#`P,#(P-C8Q(#`P,#`P(&X-
M"G1R86EL97(-/#P-+U-I>F4@,C(-+TE$6SPV9&0S93<V,S1B-61D,V,T,&,S
M-S<R9#(V.3`S-#@P.3X\-F1D,V4W-C,T8C5D9#-C-#!C,S<W,F0R-CDP,S0X
<,#D^70T^/@US=&%R='AR968-,3<S#24E14]&#3\_
`
end

</PDF>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
